Systemic lupus erythematosus (SLE) is a kind of autoimmune disease with a strong genetic predisposition caused by complicated factors, it is also considered as an inflammatory disease caused by the mediation and deposition of immune complexes (ICs), leading to damage of multiple organs[@b1]. In different races or regions, the morbidity rate of SLE is quite different[@b2][@b3], it is about 31-70/100,000 across China[@b4], while it is 7-71/100,000 in Europeans[@b5] and it increases to 200/100,000 in African population[@b5]. The etiology and pathogenesis of SLE is unclear yet, it is generally accepted that both genetic and environmental factors are involved in the development of this complex disease[@b6]. Since the end of last century, scientists were trying to use genetic linkage analysis to investigate the mechanism of SLE, a number of susceptibility area in SLE had been found such as 1q23[@b7], 1q41[@b8], 4p16[@b9], 11q14[@b10], 12q24[@b11]. Linkage analysis for SLE had made some achievements, but it is not easy to find real susceptibility genes because of large positioning areas. Then, candidate gene association studies (CGASs), in which single-nucleotide polymorphisms (SNPs) were assayed in cases and controls, were widely used and found some valuable susceptibility genes such as *IL-6*[@b12], *TLR2*[@b13], *VDR*[@b14], *CTLA-4*[@b15], *FCGR2A*[@b16], *FCGR2B*[@b17], *PELI1*[@b18], *IKZF3*[@b19]. More recently, genome-wide association studies (GWAS) have been the powerful approach and found a lot of susceptibility genes and SNPs for SLE[@b20][@b21][@b22][@b23][@b24][@b25][@b26][@b27].

Among these genes/proteins, FC gamma Receptor (*FCγR*) is a member of immunoglobulin superfamily, and it is very important to bind *FCγR* with the Fc protein of Immunoglobulin G (IgG), because *FCγR* binding may activate biological reaction, such as phagocytosis[@b28]. The human 1q21-23 locus contains 5 *FCGR* genes (*FCGR2A*, 2B, 2C, 3A and 3B) encoding the *FCγRII*and *FCγRIII* receptor**·**families[@b29]. FCγRs mediate clearance of immune complexes and have been strongly implicated in the pathogenesis of SLE and lupus nephritis[@b30]. Thus the genes that encode these receptors have been the focus of many genetic studies in SLE[@b31].

*FCGR*s were not genome-wide significantly identified by any GWAS above, and the results were not always consistent by candidate gene association study. The inconsistency of findings is related to many factors, such as the selecting of the sample, the size of sample and the dealing of the statistics, etc. Therefore, in order to reduce the limitations of single study and to overcome the possible random errors, we performed a large-scale meta-analysis involving different ethnics. Among all the studies, there were 5082 cases and 4951 controls to evaluate the relationship between *FCGR2A* rs1801274 and SLE and there were 2970 cases and 4197 controls for *FCGR2B* rs1050501. For *FCGR3A* rs396991 and *FCGR3B* NA1**·**NA2, there were 5694 cases and 6450 controls, 1692 cases and 1899 controls, respectively. The purpose of this study is to analyze whether the polymorphisms of *FCGR*s are susceptibility to SLE. We also made efforts to find the best-fit association model among the additive, recessive and dominant models for the polymorphisms.

Results
=======

Studies included in the meta-analysis
-------------------------------------

In this meta-analysis, totally 436 relevant articles were found from PubMed, of which 337 were excluded because they were unrelated articles. Studies investigating other *FCGR* gene polymorphisms were also excluded[@b17][@b32][@b33][@b34][@b35][@b36]. One more article was also excluded because there was no detail genotyping data[@b37]. After filtering, 35 eligible articles were finally included[@b16][@b33][@b38][@b39][@b40][@b41][@b42][@b43][@b44][@b45][@b46][@b47][@b48][@b49][@b50][@b51][@b52][@b53][@b54][@b55][@b56][@b57][@b58][@b59][@b60][@b61][@b62][@b63][@b64][@b65][@b66][@b67][@b68][@b69]. The flow chart of selecting articles process is presented in [Fig. 1](#f1){ref-type="fig"}. Therefore, there were 34 studies with 5082 cases and 4951 controls to evaluate the relationship between *FCGR2A* rs1801274 polymorphism and SLE. For *FCGR2B* rs1050501 polymorphism, there were 13 studies involving a total of 2970 cases and 4197 controls. For *FCGR3A* rs396991 polymorphism and *FCGR3B* NA1**·**NA2 polymorphism, 26 studies (5694 cases and 6450 controls) and 11 studies (1692 cases and 1899 controls) were available, respectively. The basic information of these included studies genotype distributions and the allele frequencies are showed in [Table 1](#t1){ref-type="table"}.

Meta-analysis results
---------------------

### *FCGR2A* rs1801274 polymorphism and SLE risk

Test of heterogeneity in the overall population is not significant (P = 0.109, I2 = 23.70%), suggesting fixed effect model could be used. A strong association was found between rs1801274 and SLE under the allelic model in the overall population (OR = 0.879 per A allele, 95%CI: 0.819--0.943, P = 3.31 × 10^−4^, [Table 2](#t2){ref-type="table"}, [Fig. 2a](#f2){ref-type="fig"}). Stratification analysis by ethnicity showed significant association between rs1801274 and SLE in Caucasian (OR = 0.845 per A allele, 95%CI: 0.766--0.932, P = 8.08 × 10^−4^, [Table 2](#t2){ref-type="table"}, [Fig. 2a](#f2){ref-type="fig"}). And we also observed association between this polymorphism and SLE in African Americans (OR = 0.575 per A allele, 95%CI; 0.429--0.774, P = 2.73 × 10^−4^, [Table 2](#t2){ref-type="table"}, [Fig. 2a](#f2){ref-type="fig"}) and in Asian population (OR = 0.896 per A allele, 95%CI: 0.822--0.977, P = 0.013, [Table 2](#t2){ref-type="table"}, [Fig. 2a](#f2){ref-type="fig"}). No significant association was found in this meta-analysis between the polymorphism and the risk of SLE in African population (OR = 0.853 per A allele, 95%CI: 0.642--1.132, P = 0.271, [Table 2](#t2){ref-type="table"}, [Fig. 2a](#f2){ref-type="fig"}). We also tested the dominant and recessive models of A allele in the overall, European, Asian and African populations, these results showed that the association was more significant in the recessive model than the dominant model in the overall population ([Table 2](#t2){ref-type="table"}, [Supplementary Fig. S1a](#S1){ref-type="supplementary-material"}, [Fig. S2a](#S1){ref-type="supplementary-material"}).

### *FCGR2B* rs1050501 polymorphism and SLE risk

To assess the association of *FCGR2B* rs1050501 polymorphism with SLE, 13 studies were included in this meta-analysis with 2970 cases and 4197 controls, however, we identified publication bias while the study by Kobavashi T *et al*.[@b59] was included (Begg's Test: Z = 2.14, P = 0.033), therefore, this study was removed in the final analysis with 2899 cases and 4153 controls. After exclusion, the Begg's test showed no deviation (Z = 1.58, P = 0.115) ([Supplementary Table S1](#S1){ref-type="supplementary-material"}).

A very significant association was identified between rs1050501 and SLE under the recessive genotypic model of C allele in the overall population (CC vs CT/TT, OR = 1.754, 95%CI: 1.422--2.165, P = 1.61 × 10^−7^, [Fig. 2b](#f2){ref-type="fig"}, [Table 3](#t3){ref-type="table"}) and in Asian population (CC vs CT/TT, OR = 1.784, 95%CI; 1.408--2.261, P = 1.67 × 10^−6^, [Table 3](#t3){ref-type="table"}, [Fig. 2b](#f2){ref-type="fig"}), these associations were not significant under dominant model, suggesting the recessive association model was fit for rs1050501_C ([Table 3](#t3){ref-type="table"}). In allelic test model, Significant association between rs1050501 and SLE was identified in the overall population (OR = 1.236 per C allele, 95%CI: 1.069--1.429, P = 6.93 × 10^−3^, [Table 3](#t3){ref-type="table"}, [Supplementary Fig. S2b](#S1){ref-type="supplementary-material"}), and in the Asian population (OR = 1.326 per C allele, 95%CI: 1.095--1.604, P = 6.14 × 10^−3^, [Table 3](#t3){ref-type="table"}, [Supplementary Fig. S2b](#S1){ref-type="supplementary-material"}) and in African population (OR = 1.749 per C allele, 95%CI: 1.153--2.655, P = 8.54 × 10^−3^, [Table 3](#t3){ref-type="table"}, [Supplementary Fig. S2b](#S1){ref-type="supplementary-material"}).

### *FCGR3A* rs396991 polymorphism and SLE risk

There were 26 studies with 5694 cases and 6450 controls in our meta-analysis to evaluate the relationship between *FCGR3A* rs396991 polymorphism and SLE. Firstly, we tested the dominant and recessive models to estimate the relation between rs396991 and SLE risk ([Table 4](#t4){ref-type="table"}). We found that rs396991 were significant association with the susceptibility to SLE in overall population in recessive model of T allele (TT vs TG/GG, OR = 1.263, 95%CI: 1.123--1.421, P = 9.62 × 10^−5^, [Table 4](#t4){ref-type="table"}, [Fig. 2c](#f2){ref-type="fig"}), and in Caucasian population (TT vs TG/GG, OR = 1.394, 95%CI: 1.087--1.789, P = 9.05 × 10^−3^) and in mixed population (TT vs TG/GG, OR = 1.585, 95%CI: 1.122--2.239, P = 9.05 × 10^−3^). Similarly, recessive model is the best fit for the association of rs396991_T, because we didn't observe any association under dominant model in any populations ([Table 4](#t4){ref-type="table"}). We also tested the allelic model to observe the relationship between rs396991 and SLE. The significant association was seen between rs396991 and SLE in the overall population (OR = 1.17 per T allele, 95%CI: 1.059--1.291, P = 1.94 × 10^−3^, [Table 4](#t4){ref-type="table"}, [Supplementary Fig. S2c](#S1){ref-type="supplementary-material"}). And we also found trend of association between this polymorphism and SLE in the stratified analysis of ethnicity: (Caucasian, OR = 1.259 per T allele, P = 0.039; Asian population, OR = 1.152 per T allele, P = 0.05, [Table 4](#t4){ref-type="table"}, [Fig. 2c](#f2){ref-type="fig"}).

### *FCGR3B* NA1**·**NA2 copy number polymorphism and SLE risk

Totally, 11 studies included 1692 cases and 1899 controls were in our meta-analysis to assess the relation between *FCGR3B* NA1**·**NA2 copy number polymorphism and SLE. The meta-analysis indicated that NA1**·**NA2 was modestly associated with SLE in overall population (allele genetic model: OR = 0.851 per NA1, 95%CI: 0.772--0.938, P = 1.2 × 10^−3^, [Table 5](#t5){ref-type="table"}, [Fig. 2d](#f2){ref-type="fig"}; recessive model of NA1: OR = 0.799, 95%CI: 0.685--0.933, P = 0.005, [Table 5](#t5){ref-type="table"}, [Supplementary Fig. S2d](#S1){ref-type="supplementary-material"}). Analysis by population showed that NA1**·**NA2 was modestly associated with SLE in Asian by three models (allele genetic model: OR = 0.785, 95%CI: 0.697--0.883, P = 6.07 × 10^−5^, [Table 5](#t5){ref-type="table"}, [Fig. 2d](#f2){ref-type="fig"}; dominant model: OR = 0.684, 95%CI: 0.549--0.853, P = 7.2 × 10^−4^, [Table 5](#t5){ref-type="table"}, [Supplementary Fig. S1d](#S1){ref-type="supplementary-material"}; recessive model: OR = 0.756, 95%CI: 0.635--0.898, P = 0.002, [Table 5](#t5){ref-type="table"}, [Supplementary Fig. S2d](#S1){ref-type="supplementary-material"}).

Allele frequency of the 3 SNPs and comparing to the 1000 genome population
--------------------------------------------------------------------------

In [Table 6](#t6){ref-type="table"}, we showed the distinct difference of allele frequencies in Asian, Caucasian, African and African American population in the meta-analysis of the 3 SNPs. The allele frequencies of the 3 SNPs in Asian, Caucasian, African and African American population in the meta--analysis were consistent with the allele frequencies in 1000 Genome Project EUR (European ancestry), ASN (Asian ancestry), AFR (African ancestry), ASW (Americans of African Ancestry), respectively.

Publication bias and Sensitivity analysis
-----------------------------------------

Begg's funnel plot and Egger's test were performed to estimate publication bias. There was no obvious evidence of symmetry from the shapes of the funnel plots ([Fig. 3](#f3){ref-type="fig"}), and showed no evidence of publication bias in rs1801274 polymorphism (P = 0.594), rs396991 polymorphism (P = 0.252), NA1**·**NA2 polymorphism (P = 0.213), and rs1050501 polymorphism (P = 0.115, after excluded the study by Kobavashi T *et al*.[@b59]) under allele genetic model in our meta-analysis ([Fig. 3a](#f3){ref-type="fig"}--d). We also conducted sensitivity analysis to assess the influence of individual studies on the pooled ORs. We found the pooled OR was not substantially altered, when any one study was deleted ([Fig. 4a--d](#f4){ref-type="fig"}).

Discussion
==========

In this study, we conducted a meta-analysis of the association between *FCGR2A, 2B, 3A* and *3B* polymorphisms and SLE susceptibility. We found that C allele of rs1050501 (*FCGR2B*) and T allele of rs396991 (*FCGR3A*) strongly increase the risk of SLE. We also found significant association between *FCGR2A* rs1801274, *FCGR3B* copy number polymorphism NA1**·**NA2, and SLE in the overall population.

SNP rs1801274 is a missense mutation in *FCGR2A* gene on chromosome 1q23.3 (161479745), which encodes substitution of histidine (H) by arginine (R) in the IgG-binding domain of FcgRIIa and it was reported that FcgRIIa-R has a lower binding affinity for IgG than FcgRIIa-H[@b68]. In our study, we found *FCGR2A* rs1801274 contributes to SLE susceptibility in overall population. And in the subgroup analysis, the polymorphism was associated with SLE in Asian, Caucasian, and African Americans but not in African population, however, there were only 3 studies for African population in this meta-analysis, consisting only 190 cases and 198 controls, and the effect direction of A allele in African population is the same as that in the overall population. Previous study such as by Karassa FB *et al*.[@b70] presented the association between *FCGR2A* rs1801274 and SLE of Caucasian descent, but it was less clear in subjects of Asian or African descent. Another study[@b71] found a significant association of rs1801274 G allele and increased SLE risk in all groups, and a clear effect of G allele on SLE was shown in European and Asian, these results were consistent with our study. We also confirmed the findings from Zhou XJ[@b65] that investigated the association between rs1801274 and SLE in Chinese population. In many ways, we suggest that rs1801274 was associated with SLE, especially in Caucasian and Asian population. As for other populations, more studies were needed to evaluate association between the polymorphism and SLE. It's likely that such differences may, at less in part, be attributable to the ethnic difference.

GWAS have found that there were significant associations between *FCGR2A* rs1801274 and Kawasaki disease[@b72] and Inflammatory bowel disease (P = 2.12 × 10^−38^, OR = 1.12)[@b73] and there were genome-wide significant associations between the SNP and Ulcerative colitis in European[@b74], and Japanese population[@b75]. There was only one genome-wide association study between *FCGR2A* and SLE, however, SNP rs1801274 was not genome-wide significant[@b27].

FcgRIIb is an inhibitory receptor mediating B-cell function via an immune receptor tyrosine-based inhibitory motif [@b59]. FcgRIIb is the only FcgR that transmits an inhibitory signal and is expressed in B cells and myelomonocytic cells[@b57]. *FCGR2B* rs1050501 (c.695T \> C) codes a non-synonymous substitution, Ile232Thr (I232T) on chromosome 1q23.3 (161644048), our meta-analysis showed that C allele significantly increased the risk of SLE under recessive association model and allelic test model in overall population ([Table 3](#t3){ref-type="table"}, [Fig. S2a](#S1){ref-type="supplementary-material"}; [Supplementary Fig. S2b](#S1){ref-type="supplementary-material"}). By subgroup analysis, the association was also found under allelic genetic model and recessive model in Asian populations, but not in Caucasians under allelic genetic model. In 2004, Chu ZT *et al*.[@b57] had found rs1050501 was significant associated with SLE in Chinese population. These results were in agreement with Lee YH *et al*.[@b76] that indicated the C allele significantly increased the risk of SLE in Asian population. Therefore, it was suggested that the association between *FCGR2B* rs1050501 and SLE was on the basis of ethnicity, and the C allele is a risk for SLE in Asian.

FcγRIIIa is expressed on the surfaces of natural killer (NK) cells, monocytes and macrophages and binds to IgG1 and IgG3 subclasses[@b66]. *FCGR3A* rs396991 is a missense mutation on chromosome 1q23.3 (161514792), leading to a valine (V) substitution for phenylalanine (F) at amino acid residue 176 (including the leader sequence)[@b66]. In our meta-analysis, it suggested that a significant association between *FCGR3A* rs396991_T and SLE in overall population under recessive association models and allele genetic model ([Table 4](#t4){ref-type="table"}, [Fig. 2c](#f2){ref-type="fig"}; [Supplementary Fig. S2c](#S1){ref-type="supplementary-material"}). Previous study[@b77] had suggested a modest trend of SLE predisposition for *FCGR3A* rs396991 in 1,261 SLE patients and 1,455 disease-free controls but with significant between-study heterogeneity. In addition, we observed trend of association between this polymorphism and SLE in the stratified analysis of ethnicity in Caucasian and Asian population, which was consistent with the study of Li *et al*.[@b78]. However, the association was not confirmed in the population of African and African American.

The copy number variation (NA1**·**NA2) in *FCGR3B* has shown to influence the interaction between FcγRIIIb and human IgG[@b61]. Individuals who are homozygous for NA1 allele has greater phagocytosis of IgG opsonized targets than that of NA2 homozygous individuals. Our meta-analysis illustrated a modest association between this copy number polymorphism and SLE in overall population by allele genetic model and recessive model. Analysis by population showed that NA1**·**NA2 was associated with SLE in Asians by three models. This association was not observed in a small sample size of 165 Chinese patients with SLE and 129 healthy controls by Chu ZT *et al*.[@b57]. To further explain the differences, we compared frequency between our meta analysis and those from Chu ZT *et al*.[@b57] in [Table 1](#t1){ref-type="table"}, From this table, we could tell the frequencies were consistent between the two, the sample size might have been responsible for the different results. Besides, we didn't find an association between *FCGR3B* NA1**·**NA2 polymorphism and SLE in Caucasian.

Though we tried to control the potential bias of publications and populations. There were still have several limitations to be taken into consideration in this meta-analysis. Firstly, although the overall sample size is large, the size of each study is relatively small, with the smallest sample of 30 cases and 31 controls. Secondly, the meta-analysis for ethnicity included data more from population with Caucasian and Asian origin, and the findings are applicable to only these populations, more studies are required in other populations. Furthermore, the mechanism of SLE is considered to be sophisticated, including gene-gene and gene-environment interactions. More studies with enough statistical power are needed for deeply evaluation. Lastly, publication bias might affect the results, because the studies that found any negative results may not have been published.

Despite the limitations, this meta-analysis illustrated that C allele of *FCGR2B* rs1050501 and T allele of *FCGR3A* rs396991 might contribute to susceptibility and development of SLE, and were under recessive association model. While, A allele of *FCGR2A* rs1801274 and *FCGR3B* NA1 were associated with SLE and reduced the risk of SLE. Considering the limited samples in Africans and African Americans in this meta-analysis, studies with larger sample size including diverse ethnic populations are still required to investigate the association between *FCGR*s genes polymorphisms and SLE in the future.

Methods
=======

Identification of eligible studies
----------------------------------

We aimed to analyze the association between *FCGR2A* (SNP rs1801274), *FCGR2B* (SNP rs1050501), *FCGR3A* (SNP rs396991), *FCGR3B* copy number polymorphism (NA1/NA2) polymorphisms and SLE. Therefore, all published literatures before December 2015 that investigated the association between these polymorphisms and SLE risk were searched using the PubMed engine (National Center for Biotechnology, National Library of Medicine). We looked for the articles with keywords "*FCGR2A*", "*FCGR2B*", "*FCGR3A*", "*FCGR3B*", "*FCγR*s", "polymorphism" in combination with "Systemic Lupus erythematosus" or "SLE". Finally, we extracted data from the published articles, not from conference abstracts or any meetings.

Data extraction
---------------

All studies should meet the following conditions: 1) case-control study; 2) with original data to calculate genotype counts and odds ratio (OR); 3) the diagnosis of SLE patients according to the American College of Rheumatology criteria[@b79][@b80]. The following information is shown in our study: first author, year of publication, ethnicity, sample size of cases and controls, allele frequency and genotype frequency.

Statistical analysis
--------------------

The allele frequencies of polymorphisms from each study were calculated by the allele counting method. Pooled ORs and 95% confidence intervals (CIs) were used to evaluate the strength of association between polymorphisms and SLE risk for every eligible study. Heterogeneity was evaluated using the I^2^ metric, which ranges between 0 and 100% (25%, low heterogeneity; 50%, moderate; 75%, high heterogeneity)[@b81]. If the P value for heterogeneity test was higher than 0.01, the fixed effect model was used to weight of each study. Moreover, the random effect model was also used. In this meta-analysis, P value of less than 0.05 was considered a statistically significant.

In order to get better search results, we evaluated possible publication bias by Egger's linear regression text[@b82]. P value \< 0.05 was considered representative of statistical publication bias[@b82]. We also used a funnel plot to evaluate the publication bias by Begg's test[@b83]. For sensitivity analysis, removed one study from the total and tested residual studies. Statistical analysis was carried out using the software program STATA10.1 (Stata Corporation, College Station, Texas).
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###### The basic information of every studies included in this meta-analysis.

  Polymorphismsand study          Journal         Year       Ethnicity       Sample size   Genotypes   Allele frequencies (%)                                                                                                      
  ------------------------ --------------------- ------ ------------------- ------------- ----------- ------------------------ ------------- ------------- ------------- ------------- ------------- --------- --------- --------- ---------
  **rs1801274(FCGR2A)**                                                                                        **AA**             **AG**        **GG**        **AA**        **AG**        **GG**       **A**     **G**     **A**     **G**
  Vigato-Ferreira IC           Autoimmunity       2014       Caucasian           157          160                23                 59            75            35            43            82         0.334     0.666     0.353     0.647
  Dijstelbloem HM             Arthritis Rheum     2000       Caucasian           230          154                54                 108           68            42            80            32         0.470     0.530     0.532     0.468
  Zuñiga R                    Arthritis Rheum     2001       Caucasian           67           53                 5                  39            23            11            28            14         0.366     0.634     0.472     0.528
  Seligman VA                 Arthritis Rheum     2001       Caucasian           76           186                10                 49            17            28            114           44         0.454     0.546     0.457     0.543
  Seligman VA                 Arthritis Rheum     2001       Caucasian           48           55                 7                  29            12            10            24            21         0.448     0.552     0.400     0.600
  Manger K                     Ann Rheum Dis      2002       Caucasian           140          187                46                 55            39            53            84            50         0.525     0.475     0.508     0.492
  Botto M                    Clin Exp Immunol     1996       Caucasian           215          259                46                 97            72            57            120           82         0.440     0.560     0.452     0.548
  Duits A                     Arthritis Rheum     1995       Caucasian           95           69                 18                 50            27            22            36            11         0.453     0.547     0.580     0.420
  Norsworthy P                Arthritis Rheum     1999       Caucasian           195          283                32                 96            67            62            131           90         0.410     0.590     0.451     0.549
  Smyth LJ                     Ann Rheum Dis      1997       Caucasian           81           66                 10                 49            22            12            38            16         0.426     0.574     0.470     0.530
  Smyth LJ                     Ann Rheum Dis      1997       Caucasian           42           52                 14                 16            12            20            24             8         0.524     0.476     0.615     0.385
  González-Escribano MF      Eur J Immunogenet    2002       Caucasian           276          194                64                 137           75            59            86            49         0.480     0.520     0.526     0.474
  Zhou XJ                          Lupus          2011         Asian             589          477               238                 269           82            209           220           48         0.632     0.368     0.669     0.331
  Kobavashi T                  J Periodontol      2007         Asian             71           44                 34                 31             6            28            16             0         0.697     0.303     0.818     0.182
  Chu ZT                      Tissue Antigens     2004         Asian             163          129                72                 70            21            53            58            18         0.656     0.344     0.636     0.364
  Kyogoku C                   Arthritis Rheum     2002         Asian             193          303               113                 72             8            197           95            11         0.772     0.228     0.807     0.193
  Siriboonrit U               Tissue Antigens     2003         Asian             87           187                37                 40            10            93            76            18         0.655     0.345     0.701     0.299
  Seligman VA                 Arthritis Rheum     2001         Asian             57           40                 11                 37             9             6            27             7         0.518     0.482     0.488     0.513
  Salmon JE                   Arthritis Rheum     1999         Asian             148          97                 70                 66            12            41            47             9         0.696     0.304     0.665     0.335
  Hatta Y                       Genes Immun       1999         Asian             81           217                49                 30             2            139           71             7         0.790     0.210     0.804     0.196
  Hatta Y                       Genes Immun       1999         Asian             69           93                 42                 26             1            62            28             3         0.797     0.203     0.817     0.183
  Lee HS                       Rheumatology       2003         Asian             299          144               131                 114           54            67            66            11         0.629     0.371     0.694     0.306
  Botto M                    Clin Exp Immunol     1996         Asian             46           49                 18                 23             5            24            20             5         0.641     0.359     0.694     0.306
  Yun HR                           Lupus          2001         Asian             300          197               132                 114           54            82            99            16         0.630     0.370     0.668     0.332
  Yap S                            Lupus          1999         Asian             175          108                59                 91            25            28            63            17         0.597     0.403     0.551     0.449
  Yap S                            Lupus          1999         Asian             50           50                 20                 26             4            21            21             8         0.660     0.340     0.630     0.370
  Chen JY                      Ann Rheum Dis      2004         Asian             329          311               125                 155           49            130           144           37         0.616     0.384     0.650     0.350
  Zidan HE                     Mol Biol Rep       2014        African            90           90                 20                 45            25            22            50            18         0.472     0.528     0.522     0.478
  Seligman VA                 Arthritis Rheum     2001        African            30           31                 9                  12             9             6            15            10         0.500     0.500     0.435     0.565
  Botto M                    Clin Exp Immunol     1996        African            70           77                 8                  37            25            17            35            25         0.379     0.621     0.448     0.552
  Seligman VA                 Arthritis Rheum     2001   mixed population        216          318                38                 131           47            50            185           83         0.479     0.521     0.448     0.552
  Seligman VA                 Arthritis Rheum     2001     Non-Caucasian         140          132                28                 82            30            22            71            39         0.493     0.507     0.436     0.564
  Salmon J                     J Clin Invest      1996   African Americans       43           39                 4                  23            16            14            15            10         0.360     0.640     0.551     0.449
  Salmon J                     J Clin Invest      1996   African Americans       214          100                37                 97            80            27            50            23         0.400     0.600     0.520     0.480
  **rs1050501(FCGR2B)**                                                                                        **CC**             **CT**        **TT**        **CC**        **CT**        **TT**       **C**     **T**     **C**     **T**
  Pradhan V                  Indian J Med Res     2011         Asian             80           80                 16                 49            15            10            52            18         0.506     0.494     0.450     0.550
  Koga M                        J Hum Genet       2011         Asian             282          222                29                 103           150            9            85            128        0.285     0.715     0.232     0.768
  Willcocks LC                     PNAS           2010         Asian             819         1026                60                 284           475           57            404           565        0.247     0.753     0.252     0.748
  Kobavashi T                  J Periodontol      2007         Asian             71           44                 4                  26            41             0             6            38         0.239     0.761     0.068     0.932
  Ji-Yih Chen                 Arthritis Rheum     2006         Asian             351          372                39                 123           189           22            144           206        0.286     0.714     0.253     0.747
  Chu ZT                      Tissue Antigens     2004         Asian             108          85                 11                 48            49             4            30            51         0.324     0.676     0.224     0.776
  Kyogoku C                   Arthritis Rheum     2002         Asian             193          303                21                 66            106           16            104           183        0.280     0.720     0.224     0.776
  Siriboonrit U               Tissue Antigens     2003         Asian             79           165                12                 29            38            12            56            97         0.335     0.665     0.242     0.758
  Magnusson V                 Arthritis Rheum     2004       Caucasian           263          228                7                  67            189            4            53            171        0.154     0.846     0.134     0.866
  Willcocks LC                     PNAS           2010       Caucasian           326         1296                9                  48            269           13            232          1051        0.101     0.899     0.100     0.900
  Li X                        Arthritis Rheum     2003       Caucasian           148          137                6                  30            112            4            27            106        0.142     0.858     0.128     0.872
  Zidan HE                     Mol Biol Rep       2014        African            90           90                 32                 39            19            17            44            29         0.572     0.428     0.433     0.567
  Li X                        Arthritis Rheum     2003   African-American        160          149                14                 49            97            17            53            79         0.241     0.759     0.292     0.708
  **rs396991(FCGR3A)**                                                                                         **TT**             **TG**        **GG**        **TT**        **TG**        **GG**       **T**     **G**     **T**     **G**
  Brambila-Tapia AJ            Rheumatol Int      2011       Caucasian           94           98                 61                  5            28            52             8            38         0.676     0.324     0.571     0.429
  Dong C                    Arthritis Rheumatol   2014       Caucasian           834         1185               392                 370           72            517           564           104        0.692     0.308     0.674     0.326
  Dijstelbloem HM             Arthritis Rheum     2000       Caucasian           230          154                92                 108           30            66            73            15         0.635     0.365     0.666     0.334
  Zuñiga R                    Arthritis Rheum     2001       Caucasian           67           53                 25                 38             4            15            26            12         0.657     0.343     0.528     0.472
  Seligman VA                 Arthritis Rheum     2001       Caucasian           78           207                37                 30            11            55            102           50         0.667     0.333     0.512     0.488
  Seligman VA                 Arthritis Rheum     2001       Caucasian           55           57                 25                 15            15            30            21             6         0.591     0.409     0.711     0.289
  Manger K                     Ann Rheum Dis      2002       Caucasian           140          187                55                 64            21            62            75            50         0.621     0.379     0.532     0.468
  Wu J                         J Clin Invest      1997       Caucasian           200          113                87                 92            21            29            69            15         0.665     0.335     0.562     0.438
  González-Escribano MF      Eur J Immunogenet    2002       Caucasian           276          194               101                 131           44            66            104           24         0.603     0.397     0.608     0.392
  Dai M                       Int J Rheum Dis     2013         Asian             732          886               376                 308           48            381           427           78         0.724     0.276     0.671     0.329
  Kobavashi T                  J Periodontol      2007         Asian             71           44                 43                 22             6            24            15             5         0.761     0.239     0.716     0.284
  Chu ZT                      Tissue Antigens     2004         Asian             163          129                76                 74            13            48            63            18         0.693     0.307     0.616     0.384
  Kyogoku C                   Arthritis Rheum     2002         Asian             193          303               110                 76             7            145           132           26         0.767     0.233     0.696     0.304
  Siriboonrit U               Tissue Antigens     2003         Asian             87           187                42                 35            10            64            96            27         0.684     0.316     0.599     0.401
  Seligman VA                 Arthritis Rheum     2001         Asian             59           41                 22                 29             8            12            22             7         0.619     0.381     0.561     0.439
  Salmon JE                   Arthritis Rheum     1999         Asian             148          97                 44                 81            23            19            64            14         0.571     0.429     0.526     0.474
  Hatta Y                       Genes Immun       1999         Asian             81           217                43                 34             4            100           99            18         0.741     0.259     0.689     0.311
  Hatta Y                       Genes Immun       1999         Asian             69           93                 37                 29             3            46            38             9         0.746     0.254     0.699     0.301
  Lee EB                         Rheum Int        2002         Asian             145          75                 89                 51             5            40            29             6         0.790     0.210     0.727     0.273
  Lee HS                       Rheumatology       2003         Asian             299          144                90                 163           46            52            77            15         0.574     0.426     0.628     0.372
  Yun HR                           Lupus          2001         Asian             300          197                90                 164           46            71            104           22         0.573     0.427     0.624     0.376
  Chen JY                      Ann Rheum Dis      2004         Asian             302          311               119                 138           45            133           146           32         0.623     0.377     0.662     0.338
  Dong C                    Arthritis Rheumatol   2014   African-American        648          953               289                 283           76            413           431           109        0.664     0.336     0.659     0.341
  Seligman VA                 Arthritis Rheum     2001   mixed population        233          348                97                 96            40            108           172           68         0.622     0.378     0.557     0.443
  Seligman VA                 Arthritis Rheum     2001     Non-Caucasian         155          141                60                 66            29            53            70            18         0.600     0.400     0.624     0.376
  Seligman VA                 Arthritis Rheum     2001        African            35           36                 11                 19             5             7            25             4         0.586     0.414     0.542     0.458
  **NA1/NA2**                                                                                               **NA1·NA1**         **NA1·NA2**   **NA2·NA2**   **NA1·NA1**   **NA1·NA2**   **NA2·NA2**   **NA1**   **NA2**   **NA1**   **NA2**
  Kobavashi T                  J Periodontol      2007         Asian             71           44                 20                 46             5            20            19             5         0.606     0.394     0.670     0.330
  Chu ZT                      Tissue Antigens     2004         Asian             163          129                46                 90            29            41            74            14         0.552     0.448     0.605     0.395
  Kyogoku C                   Arthritis Rheum     2002         Asian             193          303                62                 98            33            116           145           42         0.575     0.425     0.622     0.378
  Siriboonrit U               Tissue Antigens     2003         Asian             87           187                30                 39            18            85            82            20         0.569     0.431     0.674     0.326
  Pradhan V                   Int J Rheum Dis     2010         Asian             80           80                 20                 32            28            18            32            30         0.450     0.550     0.425     0.575
  Hatta Y                       Genes Immun       1999         Asian             81           217                23                 38            20            92            100           25         0.519     0.481     0.654     0.346
  Hatta Y                       Genes Immun       1999         Asian             69           93                 18                 33            18            44            39            10         0.500     0.500     0.683     0.317
  Chen JY                      Ann Rheum Dis      2004         Asian             302          311               117                 132           53            119           145           47         0.606     0.394     0.616     0.384
  Dijstelbloem HM             Arthritis Rheum     2000       Caucasian           230          154                42                 101           87            27            66            61         0.402     0.598     0.390     0.610
  Manger K                     Ann Rheum Dis      2002       Caucasian           140          187                13                 87            40            20            87            80         0.404     0.596     0.340     0.660
  González-Escribano MF      Eur J Immunogenet    2002       Caucasian           276          194                30                 77            169           20            75            99         0.248     0.752     0.296     0.704

###### Meta-analysis of the association between FCGR2A rs1801274 polymorphism and SLE risk.

  Population           N    A vs. G(allele model)   AA vs. AG+GG(recessive model)   AA+AG vs. GG(dominant model)                                                                                     
  ------------------- ---- ----------------------- ------------------------------- ------------------------------ --------------------- --------------- ------- --------------------- -------------- -------
  Overall              34    0.879(0.819--0.943)            3.31 × 10^−4^                      0.109               0.867(0.784--0.960)   6.14 × 10^−3^   0.214   0.843(0.739--0.961)      0.011       0.074
  Caucasian            12    0.845(0.766--0.932)            8.08 × 10^−4^                      0.439               0.775(0.655--0.917)   3.08 × 10^−3^   0.522   0.883(0.756--1.032)      0.117       0.427
  Asian                15    0.896(0.822--0.977)                0.013                          0.543               0.932(0.830--1.046)       0.232       0.658   0.767(0.604--0.975)      0.030       0.179
  African              3     0.853(0.642--1.132)                0.271                          0.438               0.836(0.428--1.633)       0.601       0.192   0.802(0.515--1.250)      0.331       0.688
  Mixed population     1     1.133(0.887--1.448)                0.318                           ---                1.144(0.721--1.817)       0.568        ---    1.27(0.844--1.911)       0.252        ---
  Non-Caucasian        1     1.259(0.898--1.765)                0.181                           ---                1.250(0.674--2.317)       0.479        ---    1.538(0.887--2.666)      0.125        ---
  African Americans    2     0.575(0.427--0.774)            2.73 × 10^−4^                      0.422               0.368(0.126--1.078)       0.068       0.100   0.519(0.324--0.831)   6.33 × 10--3   0.786

OR odd ratio, 95%CI confidence interval, P~OR~ P value for the test of association, P~h~ P value for heterogeneity analysis.

###### Meta-analysis of the association between *FCGR2B* rs1050501 polymorphism and SLE risk.

  Population          N    C vs. T(allele model)   CC vs. CT+TT(recessive model)   CC+CT vs. TT(dominant model)                                                                              
  ------------------ ---- ----------------------- ------------------------------- ------------------------------ --------------------- --------------- ------- --------------------- ------- -------
  Overall             12    1.236(1.069--1.429)                0.007                          0.030               1.754(1.422--2.165)   1.61 × 10^−7^   0.404   1.093(0.952--1.255)   0.205   0.140
  Asian               7     1.326(1.095--1.604)                0.006                          0.065               1.784(1.408--2.261)   1.67 × 10^−6^   0.630   1.149(0.957--1.380)   0.137   0.121
  Caucasian           3     1.087(0.888--1.331)                0.420                          0.812               2.055(1.106--3.817)       0.023       0.587   1.019(0.812--1.279)   0.872   0.592
  African             1     1.749(1.153--2.655)                0.009                           ---                2.369(1.198--4.685)       0.013        ---    1.777(0.907--3.479)   0.094    ---
  African-American    1     0.769(0.537--1.099)                0.149                           ---                0.745(0.353--1.569)       0.438        ---    0.733(0.467--1.152)   0.178    ---

OR odd ratio, 95%CI confidence interval, P~OR~ P value for the test of association, P~h~ P value for heterogeneity analysis.

###### Meta-analysis of the association between FCGR3A rs396991 polymorphism and SLE risk.

  Population          N    T vs. G(allele model)   TT vs. TG+GG(recessive model)   TT+TG vs. GG(dominant model)                                                                              
  ------------------ ---- ----------------------- ------------------------------- ------------------------------ --------------------- --------------- ------- --------------------- ------- -------
  Overall             26    1.17(1.059--1.291)                 0.002                          0.000               1.263(1.123--1.421)   9.62 × 10^−5^   0.003   1.114(0.933--1.331)   0.232   0.004
  Caucasian           9     1.259(1.012--1.566)                0.039                          0.000               1.394(1.087--1.789)   9.05 × 10^−3^   0.008   1.187(0.830--1.699)   0.347   0.004
  Asian               13    1.152(0.999--1.328)                0.051                          0.004               1.211(1.022--1.434)       0.027       0.036   1.164(0.884--1.533)   0.280   0.049
  African-American    1     1.022(0.880--1.186)                0.776                           ---                1.053(0.861--1.287)       0.617        ---    0.972(0.712--1.327)   0.858    ---
  Mixed population    1     1.308(1.029--1.662)                0.028                           ---                1.585(1.122--2.239)   9.05 × 10^−3^    ---    1.172(0.761--1.804)   0.471    ---
  Non-Caucasian       1     0.903(0.649--1.258)                0.548                           ---                1.049(0.656--1.677)       0.843        ---    0.636(0.336--1.204)   0.164    ---
  African             1     1.196(0.616--2.324)                0.597                           ---                1.899(0.638--5.654)       0.249        ---    0.750(0.184--3.060)   0.688    ---

OR odd ratio, 95%CI confidence interval, P~OR~ P value for the test of association, P~h~ P value for heterogeneity analysis.

###### Meta-analysis of the association between FCGR3B copy number polymorphism NA1·NA2 and SLE risk.

  Population    N    NA1 vs. NA2(allele model)   NA1·NA1 vs. NA1·NA2+NA2·NA2 (recessive model)   NA1·NA1+NA2·NA2 vs. NA2·NA2 (dominant model)                                                                             
  ------------ ---- --------------------------- ----------------------------------------------- ---------------------------------------------- --------------------- ------- ------- --------------------- -------------- -------
  Overall       11      0.851(0.772--0.938)                      1.2 × 10^−3^                                       0.004                       0.799(0.685--0.933)   0.005   0.182   0.825(0.702--0.969)      0.019       0.001
  Asian         3       0.785(0.697--0.883)                      6.07 × 10^−5^                                      0.040                       0.756(0.635--0.898)   0.002   0.116   0.684(0.549--0.853)   7.2 × 10^−4^   0.103
  Caucasian     8       1.013(0.851--1.205)                          0.888                                          0.060                       1.006(0.709--1.426)   0.974   0.885   1.021(0.806--1.292)      0.866       0.003

OR odd ratio, 95%CI confidence interval, P~OR~ P value for the test of association, P~h~ P value for heterogeneity analysis.

###### The allele frequency comparison between the meta-analysis and 1000 Genomes Project.

  Polymorphism        Populations    Meta-analysis(alleles frequencies)                                            
  ------------------- ------------- ------------------------------------ ------- ------- ------------ ------------ ----------
  SNP rs1801274       Caucasian                    0.445                  0.555   0.474     0.526      0.500(EUR)   0.5(EUR)
  Asian               0.652                        0.348                  0.697   0.303   0.722(ASN)   0.278(ASN)  
  African             0.568                        0.432                  0.602   0.398   0.512(AFR)   0.488(AFR)  
  African Americans   0.393                        0.607                  0.529   0.471   0.525(ASW)   0.475(ASW)  
  Mixed population    0.479                        0.521                  0.448   0.552                            
  Non-Caucasian       0.493                        0.507                  0.436   0.564                            
  All                 0.563                        0.437                  0.595   0.405   0.57(ALL)    0.43(ALL)   
  SNP rs1050501                                      C                      T       C         T            C           T
  Asian               0.280                        0.720                  0.248   0.752   0.255(ASN)   0.745(ASN)  
  Caucasian           0.128                        0.872                  0.107   0.893   0.123(EUR)   0.877(EUR)  
  African             0.572                        0.428                  0.433   0.567   0.248(AFR)   0.752(AFR)  
  African-American    0.241                        0.759                  0.292   0.708   0.213(ASW)   0.787(ASW)  
  All                 0.249                        0.751                  0.198   0.802   0.188(ALL)   0.812(ALL)  
  SNP rs396991                                       T                      G       T         G            T           G
  Caucasian           0.659                        0.341                  0.629   0.371   0.731(EUR)   0.269(EUR)  
  Asian               0.673                        0.327                  0.657   0.343   0.731(ASN)   0.269(ASN)  
  African-American    0.664                        0.336                  0.659   0.341   0.713(ASW)   0.287(ASW)  
  Mixed population    0.622                        0.378                  0.557   0.443                            
  Non-Caucasian       0.600                        0.400                  0.624   0.376                            
  African             0.586                        0.414                  0.542   0.458   0.785(AFR)   0.215(AFR)  
  All                 0.663                        0.337                  0.641   0.359   0.755(ALL)   0.245(ALL)  

EUR European ancestry, ASN Asian ancestry, AFR African ancestry, ASW Americans of African Ancestry, ALL All individuals from phase 1 of the 1000 Genomes Project.

[^1]: These authors contributed equally to this work.
